Compare Biogen Inc (BIIB) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Biogen Inc trades at $205.41 (market cap $30.13B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.93. Which is the better fit depends on your goals.
| BIIB | PDBC | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | — |
52-Week High | $216.63 | $18.91 |
52-Week Low | $128.93 | $12.90 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
PDBC trades at $17.87, up 0.22% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on diversified commodities, avoiding K-1 tax forms, and has seen strong institutional inflows, including a 150.6% position increase by Geneos Wealth Management in Q1 2026 (SEC filing, 2026-07-19). Recent news highlights commodities' role as an inflation hedge, with PDBC returning 37% since March 2024, though momentum has weakened recently (Seeking Alpha, 2026-06-11).
The outlook for PDBC is supported by geopolitical tensions and inflation hedging demand, but risks include commodity price volatility and Middle East conflicts. Wall Street sentiment is mixed, with a recent downgrade to hold due to fading momentum, yet institutional interest remains strong, indicating long-term confidence in commodities exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
